retatrutide phase 2 trial obesity triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28











%20powder-1.png)
















